IDEAYA Biosciences Inc. (IDYA)
18.61
0.22 (1.20%)
At close: Mar 24, 2025, 3:59 PM
18.59
-0.08%
After-hours: Mar 24, 2025, 04:37 PM EDT
1.20% (1D)
| Bid | 18 |
| Market Cap | 1.63B |
| Revenue (ttm) | 7.5M |
| Net Income (ttm) | -294.17M |
| EPS (ttm) | -3.36 |
| PE Ratio (ttm) | -5.54 |
| Forward PE | -8.81 |
| Analyst | Buy |
| Ask | 20 |
| Volume | 529,728 |
| Avg. Volume (20D) | 906,649.4 |
| Open | 18.60 |
| Previous Close | 18.39 |
| Day's Range | 18.18 - 18.89 |
| 52-Week Range | 16.95 - 44.42 |
| Beta | 0.75 |
About IDYA
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, ...
Industry Biotechnology
Sector Healthcare
IPO Date May 23, 2019
Employees 131
Stock Exchange NASDAQ
Ticker Symbol IDYA
Website https://www.ideayabio.com
Analyst Forecast
According to 13 analyst ratings, the average rating for IDYA stock is "Buy." The 12-month stock price forecast is $53, which is an increase of 184.87% from the latest price.
Stock ForecastsNext Earnings Release
IDEAYA Biosciences Inc. is scheduled to release its earnings on May 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
+0.34%
IDEAYA Biosciences shares are trading higher after...
Unlock content with
Pro Subscription
8 months ago
-3.37%
IDEAYA Biosciences shares are trading lower after the company priced a $263 million public offering of 228,572 common shares and pre-funded warrants at $35 per share.
